JP2017505622A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505622A5
JP2017505622A5 JP2016549322A JP2016549322A JP2017505622A5 JP 2017505622 A5 JP2017505622 A5 JP 2017505622A5 JP 2016549322 A JP2016549322 A JP 2016549322A JP 2016549322 A JP2016549322 A JP 2016549322A JP 2017505622 A5 JP2017505622 A5 JP 2017505622A5
Authority
JP
Japan
Prior art keywords
baff
seq
antibody molecule
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016549322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505622A (ja
JP6511459B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/013711 external-priority patent/WO2016039801A1/en
Publication of JP2017505622A publication Critical patent/JP2017505622A/ja
Publication of JP2017505622A5 publication Critical patent/JP2017505622A5/ja
Application granted granted Critical
Publication of JP6511459B2 publication Critical patent/JP6511459B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016549322A 2014-01-31 2015-01-30 新規な抗ｂａｆｆ抗体 Active JP6511459B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461934124P 2014-01-31 2014-01-31
US61/934,124 2014-01-31
PCT/US2015/013711 WO2016039801A1 (en) 2014-01-31 2015-01-30 Novel anti-baff antibodies

Publications (3)

Publication Number Publication Date
JP2017505622A JP2017505622A (ja) 2017-02-23
JP2017505622A5 true JP2017505622A5 (enExample) 2018-03-08
JP6511459B2 JP6511459B2 (ja) 2019-05-15

Family

ID=53754266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016549322A Active JP6511459B2 (ja) 2014-01-31 2015-01-30 新規な抗ｂａｆｆ抗体

Country Status (14)

Country Link
US (3) US9840543B2 (enExample)
EP (1) EP3099715B1 (enExample)
JP (1) JP6511459B2 (enExample)
KR (1) KR20160113715A (enExample)
CN (1) CN105873949B (enExample)
AU (1) AU2015315834B2 (enExample)
BR (1) BR112016014731A2 (enExample)
CA (1) CA2934965A1 (enExample)
CL (1) CL2016001742A1 (enExample)
EA (1) EA033604B1 (enExample)
IL (2) IL246113B (enExample)
MX (1) MX367661B (enExample)
PH (1) PH12016501366A1 (enExample)
WO (1) WO2016039801A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
EA033604B1 (ru) 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
WO2017015433A2 (en) * 2015-07-23 2017-01-26 Boehringer Ingelheim International Gmbh Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
WO2017223534A2 (en) * 2016-06-24 2017-12-28 Anthera Pharmaceuticals, Inc. Methods of treating iga nephropathy and henoch-schönlein purpura nephritis using a b-cell activating factor (baff) inhibitor
CN107586339B (zh) * 2016-07-06 2023-01-20 尚华科创投资管理（江苏）有限公司 一种BLyS抗体及其制备方法和应用
US10869522B2 (en) 2016-11-04 2020-12-22 Totes Isotoner Corporation Footwear, and methods of preparing same
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US20200385478A1 (en) * 2018-01-05 2020-12-10 Biograph 55, Inc. Compositions and methods for cancer immunotherapy
AU2019247511B2 (en) 2018-04-06 2025-10-16 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
US20210238295A1 (en) * 2018-04-26 2021-08-05 University Of Virginia Patent Foundation Compositions and methods for treating abdominal aortic aneurysm
CA3156803A1 (en) * 2019-10-03 2021-04-08 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
MX2022011335A (es) * 2020-03-18 2022-10-07 Kindred Biosciences Inc Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
CN113637073B (zh) * 2020-05-11 2024-04-12 上海赛比曼生物科技有限公司 Bcma抗体及其制备和应用
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
CN112516303A (zh) * 2020-11-18 2021-03-19 华中科技大学同济医学院附属协和医院 Baff抗体在制备脓毒血症药物中的应用
CN116178530A (zh) * 2021-09-26 2023-05-30 上海君实生物医药科技股份有限公司 抗体在治疗SARS-CoV-2感染的用途
CN118440195B (zh) * 2022-06-17 2025-04-08 东莞市朋志生物科技有限公司 抗脂联素抗体、检测脂联素的试剂和试剂盒
CN116041515A (zh) * 2022-09-20 2023-05-02 南京驯鹿医疗技术有限公司 一种靶向baff-r抗原的全人源抗体、单链抗体、抗原结合片段
AU2024239150A1 (en) 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
TW202544037A (zh) * 2023-12-11 2025-11-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 抗原結合蛋白
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
IL144202A0 (en) 1999-01-25 2002-05-23 Biogen Inc Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
JP5570681B2 (ja) 2004-08-31 2014-08-13 興和株式会社 抗ヒトｂａｆｆ抗体
JP4907353B2 (ja) 2004-09-15 2012-03-28 興和株式会社 Ｂａｆｆ抑制剤又は阻害剤のスクリーニング方法
WO2006031718A2 (en) 2004-09-15 2006-03-23 The Uab Research Foundation Compositions and methods for modulating rank activities
US20090215071A1 (en) * 2005-07-28 2009-08-27 Teresa Cachero Methods of targeting baff
US8617545B2 (en) 2005-10-13 2013-12-31 Biogen Idec Ma Inc. Methods for use with BAFF antagonists
AR064464A1 (es) 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
SI2315780T1 (sl) 2008-07-17 2015-11-30 Novartis Ag Sestavki in postopki uporabe za terapevtska protitelesa
US20130028897A1 (en) * 2009-04-27 2013-01-31 Ali Naji Methods for reducing the level of alloantibodies in a subject
WO2011031835A1 (en) 2009-09-09 2011-03-17 The Uab Research Foundation Chimeric dr5 polypeptides and uses thereof
IN2012DN03824A (enExample) 2009-10-30 2015-08-28 Merck Sharp & Dohme
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
CN108866101A (zh) 2011-10-28 2018-11-23 瑞泽恩制药公司 人源化il-6和il-6受体
AR090626A1 (es) 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
EA033604B1 (ru) * 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид

Similar Documents

Publication Publication Date Title
JP2017505622A5 (enExample)
JP2020500542A5 (enExample)
RU2474588C2 (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
HRP20192098T1 (hr) Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene
HRP20170038T1 (hr) Protutijela na il-6 i njihova uporaba
EP4464333A3 (en) Anti-death receptor antibodies and methods of use thereof
JP2015508757A5 (enExample)
JP2017512838A5 (enExample)
JP2016537383A5 (enExample)
JP2012501670A5 (enExample)
IL261666B1 (en) Binding proteins and methods of use thereof
MX2024013960A (es) Anticuerpos anti-ox40 y metodos de uso
HRP20220811T1 (hr) Agonistička sredstva za vezanje tnf receptora
JP2020501531A5 (enExample)
JP2018504105A5 (enExample)
JP2016531100A5 (enExample)
RU2011135422A (ru) Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний
JP2010526028A5 (enExample)
JP2017514787A5 (enExample)
RU2019115610A (ru) Антитела и полипептиды, направленные против cd127
JP2022513434A5 (enExample)
JP2014500009A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
RU2016129517A (ru) Биспецифические антитела к her2 и способы применения
PE20090689A1 (es) Anticuerpos del antagonista ox40 y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes